Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study)
- PMID: 32940209
- DOI: 10.55563/clinexprheumatol/2b73dn
Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study)
Abstract
Objectives: The AQUEOUS (Anti-phospholipid syndrome: a QUEstionnaire for yOUng patientS) study aimed to assess how the diagnosis of primary anti-phospholipid syndrome (PAPS) affects the psychosocial status of young patients.
Methods: Subjects with PAPS aged 18-45 years were invited to compile an ad hoc designed questionnaire and the Short Form-12 to assess quality of life (QoL).
Results: Ninety-two patients (83.7% females) were recruited in 10 Italian centres. Vascular and obstetric manifestations were equally represented. Nearly half of the patients perceived the need for psychological support, 89.2% when considering women after pregnancy complications. Social activities and working efficiency were reduced in APS patients, also intimacy was threatened. In all cases, fatigue appeared to be the main determinant. PAPS affected family planning, due to fears of treatment side-effects, disease hereditariness, inability to care for the newborn child. Fertility appeared to be conserved: the median time to pregnancy was 2 months; assisted reproduction techniques were pursued by 5 women. Our survey documented significantly lower rates of hospitalisation and learning disabilities in 51 children born after APS diagnosis as compared to 48 children born before. PAPS patients displayed lower QoL in physical and, to a greater extent, mental scores compared to the general Italian population. Both components were significantly lower in women and in patients with fatigue.
Conclusions: The AQUEOUS study assessed for the first time the unmet needs of young PAPS patients, enabling the development of a future "youth-focused" strategy to reduce disease burden.
Similar articles
-
Distinct features of youth-onset primary antiphospholipid syndrome.Lupus. 2021 Oct;30(12):1888-1895. doi: 10.1177/09612033211038054. Epub 2021 Oct 12. Lupus. 2021. PMID: 34634966
-
Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.Clin Rheumatol. 2019 Nov;38(11):3161-3168. doi: 10.1007/s10067-019-04670-7. Epub 2019 Jul 9. Clin Rheumatol. 2019. PMID: 31290022
-
Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.Lupus. 2015 Feb;24(2):174-9. doi: 10.1177/0961203314551809. Epub 2014 Sep 19. Lupus. 2015. PMID: 25239925
-
[Antiphosphatidylethanolamine antibody as a marker of antiphospholipid syndrome?].Presse Med. 2015 Mar;44(3):284-91. doi: 10.1016/j.lpm.2014.06.033. Epub 2014 Dec 24. Presse Med. 2015. PMID: 25542711 Review. French.
-
A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome.JNMA J Nepal Med Assoc. 2019 Mar-Apr;57(216):133-145. doi: 10.31729/jnma.4226. JNMA J Nepal Med Assoc. 2019. PMID: 31477950 Free PMC article. Review.
Cited by
-
A qualitative investigation of the experiences of patients living with antiphospholipid antibodies.Lupus. 2024 Sep;33(10):1043-1058. doi: 10.1177/09612033241265545. Epub 2024 Jul 24. Lupus. 2024. PMID: 39045728 Free PMC article.
-
Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management.Curr Rheumatol Rep. 2021 Jan 28;23(2):10. doi: 10.1007/s11926-020-00976-7. Curr Rheumatol Rep. 2021. PMID: 33511497 Free PMC article. Review.
-
Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study.ACR Open Rheumatol. 2023 Jan;5(1):28-37. doi: 10.1002/acr2.11512. Epub 2022 Dec 2. ACR Open Rheumatol. 2023. PMID: 36461647 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous